Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibodies armed with B-BiTEs
On this week's episode we’ll discuss the findings from a long-term follow up study of fludarabine, cyclophosphamide, and rituximab in IGHV-mutated CLL, learn more about the impact of genetic alterations and minimal residual disease in adults with KMT2A-rearranged B-cell precursor ALL, and discuss a pre-clinical study of reinforced immunotherapy for myeloma using a new bispecific antibody-based approach.
Podkasten Blood Podcast er innebygd på denne siden fra en åpen RSS feed. Alle filer, beskrivelser, illustrasjoner og andre metadata fra RSS-feeden tilhører podcasteieren og er ikke tilknyttet eller validert av Podplay.